Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ObesityWeek® 2019
Details on the presentations are as follows:
ObesityWeek’s special late-breaking research forum, “Emerging Pharmacological Anti-obesity Therapies,” is
- “Efficacy and Safety of the MC4R Agonist Setmelanotide in POMC Deficiency Obesity: A Phase 3 Trial,” presented by Peter Kühnen, M.D.,
Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin, Germany;
- “Efficacy and Safety of the MC4R Agonist Setmelanotide in LEPR Deficiency Obesity: A Phase 3 Trial,” presented by
Erica Van Den Akker, M.D., Ph.D., Erasmus MC-Sophia Children’s Hospital Universityin Rotterdam, Netherlands.
The same abstracts also will be presented during the Pharmacotherapy Late Breaking Poster Session on
In addition, a third poster, “Functional Characterization of Missense Variants in LEPR, POMC, & PCSK1 Genes Arising From SNV,” will be presented during the CNS Poster Session on
Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. The company recently announced positive topline results from pivotal Phase 3 clinical trials of setmelanotide, its MC4R agonist, in patients with POMC deficiency obesity and LEPR deficiency obesity. The company plans to complete its first rolling new drug application (NDA) submission to the
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements regarding Rhythm’s anticipated timing for enrollment of patients in clinical trials and submission of an NDA, its ongoing efforts related to patient identification, the timing of the release of results of clinical trials, the efficacy of setmelanotide in patients with POMC deficiency obesity, LEPR deficiency obesity, Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, or POMC epigenetic disorders, as well as new indications that we may pursue. Statements using word such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward looking statements. Such statements are subject to numerous risks and uncertainties, including but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, and expenses, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other reports we file with the
Head of Investor Relations and Corporate Communications
Stern Investor Relations, Inc.
Berry & Company Public Relations
Source: Rhythm Pharmaceuticals, Inc.